ReCode Therapeutics is a company developing non-viral nanoparticles for delivery of diverse RNA- and protein-based therapeutics to targeted tissues, and tRNA NanoCorrectors. Its aim is to create the suppressor tRNA-nanoparticle therapeutics for the correction of genetic mutations. The company focuses on the treatment of cystic fibrosis (CF) caused by nonsense mutations and primary ciliary dyskinesia (PCD).
|HQ||Menlo Park, CA, US||Map|
|Employees (est.) (Aug 2022)||74||(+11%)|
ReCode Therapeutics total Funding
ReCode Therapeutics latest funding size
Time since last funding
|2 years ago|
ReCode Therapeutics investors
|MPM Capital, Colt Ventures, OrbiMed, Hunt Technology Ventures, OUP (Osage University Partners)|
ReCode Therapeutics has 253 Twitter Followers. The number of followers has increased 9.3% month over month and increased 43.9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was ReCode Therapeutics founded?
ReCode Therapeutics was founded in 2015.
Who are ReCode Therapeutics key executives?
ReCode Therapeutics's key executives are David J. Lockhart, Julie Eastland and Vladimir G. Kharitonov.
How many employees does ReCode Therapeutics have?
ReCode Therapeutics has 74 employees.
Who are ReCode Therapeutics competitors?
Competitors of ReCode Therapeutics include Vertex Pharmaceuticals, BillionToOne and Synspira.
Where is ReCode Therapeutics headquarters?
ReCode Therapeutics headquarters is located at 1455 Adams Dr Suite 1120, Menlo Park.
Where are ReCode Therapeutics offices?
ReCode Therapeutics has offices in Menlo Park and Dallas.
How many offices does ReCode Therapeutics have?
ReCode Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies